Hangzhou HighlightII Pharmaceutical Co. Ltd. RM 301/302, BLDG 4, Hexiang Sci & Tech Center, Qiantang District Hangzhou 310018, China Re: Amendment No. 2 to Development and License Agreement dated March 21, 2023Biohaven Ltd. • February 29th, 2024 • Pharmaceutical preparations
We refer to the Development and License Agreement dated March 21, 2023 between Biohaven Therapeutics Ltd. (“Biohaven”) and Hangzhou HighlightII Pharmaceutical Co. Ltd. (“HighlightII”) relating to dual TYK2/JAK1 tyrosine kinase inhibitors, as amended (“TYK2/JAK1 License Agreement”). Capitalized terms shall have the meanings ascribed to them in the TYK2/JAK1 License Agreement unless otherwise defined herein.
